RxDoctor Payments Data

Christina Sweatt

Family · Elkton, MDNPI 1114570009

Payments from drug & device makers

$1,742in general payments, 2019–2025

Across 96 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$375
  • AbbVie$250
  • Lilly USA, LLC$187
  • AstraZeneca$125
  • Pfizer$112
  • Astellas Pharma US Inc$100
  • plus $593 from 17 others

What the payments were for

  • Food & beverage$1,63094%
  • Education$1126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,742 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$78,376
Medicare patients
152
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide135$201,213
OzempicSemaglutide97$102,254
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$42,485
FarxigaDapagliflozin Propanediol26$38,623
WegovySemaglutide26$33,800
TrulicityDulaglutide25$33,379
EliquisApixaban27$33,359
JardianceEmpagliflozin27$29,614
RybelsusSemaglutide13$27,658
LinzessLinaclotide11$8,941
TradjentaLinagliptin12$7,174
Omeprazole98$1,346
Rosuvastatin Calcium66$1,319
Atorvastatin Calcium106$1,219
Duloxetine Hcl21$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$187$234,592160 claims
Novo NordiskOzempic, Wegovy, Rybelsus$375$163,712136 claims
GSKTrelegy Ellipta$90$42,48538 claims
AstraZenecaFarxiga$125$38,62326 claims
PfizerEliquis$112$33,35927 claims
AbbVieLinzess, Synthroid$250$9,46927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →